Pair page
CJC-1295 with Tirzepatide
Mechanism-tag overlap and published literature for CJC-1295 and Tirzepatide, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
ghrhgrowth-hormone-releasing-hormone-analog
dual-gip-glp-1-receptor-agonist
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying CJC-1295 and Tirzepatide have published these mechanism-level observations. Not a co-administration recommendation.
Common pairing during active tirzepatide weight loss to preserve lean mass via GH pulsatility. Rationale: rapid weight loss produces fat + lean-mass loss; GH secretagogues may bias toward greater fat oxidation. No head-to-head tirzepatide trials; mechanistically coherent.
Quick facts
CJC-1295
Tirzepatide
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2006 | CJC-1295 | aidsmap. Lipodystrophy study halted after patient death. July 2006. (Reports the ConjuChem Phase 2 CJC-1295 trial halt.) | human trial, Phase 2 |
| 2010 | CJC-1295 | Alexopoulou O, Abs R, Maiter D. Treatment of adult growth hormone deficiency: who, why and how? A review. Acta Clin Belg. 2010;65(1):13-22. PMID: 20373593. PMID 20373593 | human study |
| 2009 | CJC-1295 | Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. PMID: 19540144. PMID 19540144 | human study |
| 2006 | CJC-1295 | Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805… PMID 16352683 | human study |
| 2006 | CJC-1295 | Abla AA, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E… PMID 16835399 | preclinical, in vivo |
| 2005 | CJC-1295 | Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology.… PMID 15817669 | preclinical, in vivo |
| 2005 | CJC-1295 | Alba M, Fintini D, Bowers CY, Parlow AF, Salvatori R. Effects of long-term treatment with growth hormone-releasing peptide-2 in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2005;289(5):E762-E767. | preclinical, in vivo |
| 2020 | CJC-1295 | Ishida J, Saitoh M, Ebner N, Springer J, Anker SD, von Haehling S. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Commun. 2020;3(1):25-37. | mechanism / discovery |
| 1995 | CJC-1295 | Izdebski J, Pinski J, Horvath JE, Halmos G, Groot K, Schally AV. Synthesis and biological evaluation of superactive agonists of growth hormone-releasing hormone. Proc Natl Acad Sci USA. 1995;92(10):4872-4876. PMID: 7761412. (Parent work on tetrasubstituted GHRH analogs.) PMID 7761412 | mechanism / discovery |
| 2023 | CJC-1295 | Alwatban MZ, Al-Lohedan HA. A review of CJC-1295 as a GHRH analog: Pharmacology and clinical relevance. Drug Des Devel Ther. 2023 (review series). | review |
| 2026 | CJC-1295 | World Anti-Doping Agency. The 2026 Prohibited List. Section S2 — Peptide Hormones, Growth Factors, Related Substances and Mimetics. wada-ama.org. | regulatory / registry |
| 2025 | CJC-1295 | U.S. Food and Drug Administration. Bulk Drug Substances That Raise Significant Safety Risks (Category 2) Under Section 503A / 503B. FDA.gov. Updated 2025. | regulatory / registry |
| 2022 | Tirzepatide | Heerspink HJL, Sattar N, Pavo I, Haupt A, Duffin KL, Yang Z, et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022;10(11)… PMID 36152639 | human trial, Phase 3 |
| 2021 | Tirzepatide | Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, et al.; SURPASS-1 Investigators. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet.… PMID 34186022 | human trial, Phase 3 |
| 2021 | Tirzepatide | Ludvik B, Giorgino F, Jódar E, Frias JP, Fernández Landó L, Brown K, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group,… PMID 34370970 | human trial, Phase 3 |
| 2021 | Tirzepatide | Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, et al.; SURPASS-4 Investigators. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 202… PMID 34672967 | human trial, Phase 3 |
| 2025 | Tirzepatide | Jastreboff AM, le Roux CW, Stefanski A, Aronne LJ, Halpern B, Wharton S, et al.; SURMOUNT-1 Investigators. Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med. 2025;392(10):958-971. PMID: 39536238. PMID 39536238 | human trial |
| 2024 | Tirzepatide | Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin WY, et al.; SURMOUNT-4 Investigators. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. PMID: 38078870. PMID 38078870 | human trial |
| 2024 | Tirzepatide | Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, et al.; SURMOUNT-OSA Investigators. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391(13):1193-1205. PMID: 38912654. PMID 38912654 | human trial |
| 2023 | Tirzepatide | Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, et al.; SURMOUNT-2 Investigators. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626. PMID: 37385275. PMID 37385275 | human trial |
| 2022 | Tirzepatide | Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al.; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. PMID: 35658024. PMID 35658024 | human trial |
| 2022 | Tirzepatide | Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, Rodríguez Á. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022;327(6):534-545. PMID: 3513… PMID 35133415 | human trial |
| 2021 | Tirzepatide | Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, et al.; SURPASS-2 Investigators. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. PMID: 34170647. PMID 34170647 | human trial |
| 2018 | Tirzepatide | Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. PMID: 30473097. PMID 30473097 | mechanism / discovery |
Related pair pages
More research context
Frequently asked
Have CJC-1295 and Tirzepatide been studied together?
Researchers have published mechanistic-level co-administration discussion of CJC-1295 and Tirzepatide. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do CJC-1295 and Tirzepatide share?
CJC-1295 and Tirzepatide do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of CJC-1295 and Tirzepatide?
CJC-1295: Not approved. Tirzepatide: Approved (T2D 2022, obesity 2023, OSA 2024). FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on CJC-1295 and Tirzepatide?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the CJC-1295 profile and the Tirzepatide profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026